JPET Assistant Professor of Medicine (Clinician-Educator)

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Jakubík, J.
Right arrow Articles by El-Fakahany, E. E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Jakubík, J.
Right arrow Articles by El-Fakahany, E. E.

Vol. 301, Issue 3, 1033-1041, June 2002

Allosteric Modulation by Persistent Binding of Xanomeline of the Interaction of Competitive Ligands with the M1 Muscarinic Acetylcholine Receptor

Jan Jakubík, Stanislav Tucek and Esam E. El-Fakahany

Division of Neuroscience Research in Psychiatry, University of Minnesota Medical School, Minneapolis, Minnesota (E.E.E.-F.); and Institute of Physiology, Academy of Sciences of the Czech Republic, Prague, Czech Republic (J.J., S.T.)

Xanomeline is a potent agonist that is functionally selective for muscarinic M1 receptors. We have shown previously that a significant fraction of xanomeline binding to membranes of Chinese hamster ovary (CHO) cells expressing the M1 receptors occurs in a wash-resistant manner and speculated that this persistent binding likely does not take place at the primary binding site on the receptor. In the present work we investigated in depth the pharmacological characteristics of this unique mode of xanomeline binding and the effects of this binding on the interaction of classical competitive ligands with the receptor in CHO cells that express the M1 muscarinic receptor. Onset of persistent binding of xanomeline to the M1 muscarinic receptor was fast and was only slightly hindered by atropine. Its dissociation was extremely slow, with a half-life of over 30 h. Although persistently bound xanomeline strongly inhibited binding of the classical antagonist N-methylscopolamine (NMS) to the receptor, there are multiple indications that this is not the result of competition at the same binding domain. Namely, wash-resistant binding of xanomeline only slightly slowed the rate of NMS association, but enhanced the rate of NMS dissociation. Moreover, preincubation with xanomeline followed by extensive washing brought about an apparent decrease in the number of NMS binding sites. Our findings are best interpreted in terms of allosteric interactions between xanomeline-persistent binding to the M1 muscarinic receptor and competitive ligands bound to the classical receptor binding site.

0022-3565/02/3013-1033$03.00/0
THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
Copyright © 2002 by The American Society for Pharmacology and Experimental Therapeutics


This article has been cited by other articles:


Home page
 Mol. Pharmacol.Home page
T. P. Kenakin
Seven Transmembrane Receptors as Nature's Prototype Allosteric Protein: De-emphasizing the Geography of Binding
Mol. Pharmacol., September 1, 2008; 74(3): 541 - 543.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
K. C. De Lorme, M. K.O. Grant, M. J. Noetzel, S. B. Polson, and E. E. El-Fakahany
Long-Term Changes in the Muscarinic M1 Receptor Induced by Instantaneous Formation of Wash-Resistant Xanomeline-Receptor Complex
J. Pharmacol. Exp. Ther., December 1, 2007; 323(3): 868 - 876.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Pharmacol.Home page
T. A. Kohout, Q. Xie, S. Reijmers, K. J. Finn, Z. Guo, Y.-F. Zhu, and R. S. Struthers
Trapping of a Nonpeptide Ligand by the Extracellular Domains of the Gonadotropin-Releasing Hormone Receptor Results in Insurmountable Antagonism
Mol. Pharmacol., August 1, 2007; 72(2): 238 - 247.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
E. Machova, J. Jakubik, E. E. El-Fakahany, and V. Dolezal
Wash-Resistantly Bound Xanomeline Inhibits Acetylcholine Release by Persistent Activation of Presynaptic M2 and M4 Muscarinic Receptors in Rat Brain
J. Pharmacol. Exp. Ther., July 1, 2007; 322(1): 316 - 323.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
P. Michal, E. E. El-Fakahany, and V. Dolezal
Muscarinic M2 Receptors Directly Activate Gq/11 and Gs G-Proteins
J. Pharmacol. Exp. Ther., February 1, 2007; 320(2): 607 - 614.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Pharmacol.Home page
J. Jakubik, E. E. El-Fakahany, and V. Dolezal
Differences in Kinetics of Xanomeline Binding and Selectivity of Activation of G Proteins at M1 and M2 Muscarinic Acetylcholine Receptors
Mol. Pharmacol., August 1, 2006; 70(2): 656 - 666.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
M. K. O. Grant and E. E. El-Fakahany
Persistent Binding and Functional Antagonism by Xanomeline at the Muscarinic M5 Receptor
J. Pharmacol. Exp. Ther., October 1, 2005; 315(1): 313 - 319.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
J. Jakubik, S. Tucek, and E. E. El-Fakahany
Role of Receptor Protein and Membrane Lipids in Xanomeline Wash-Resistant Binding to Muscarinic M1 Receptors
J. Pharmacol. Exp. Ther., January 1, 2004; 308(1): 105 - 110.
[Abstract] [Full Text] [PDF]


Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition

Copyright © 2002 by the American Society for Pharmacology and Experimental Therapeutics.